Back to Search
Start Over
Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts—Results of a Literature Review
- Source :
- Therapeutics and Clinical Risk Management. 16:57-73
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- Introduction: The risk of polypharmacy is on the rise in most industrialized countries, threatening to burden their health systems. Although many definitions exist and numerous concepts are found in literature as synonyms, the phenomenon of polypharmacy remains poorly defined. The aim of this literature review is to provide an overview of available definitions of polypharmacy, to analyse their convergences and divergences and to discuss the consequences on the assessment of the problem. Methods: A literature review was conducted to identify all published systematic reviews on definitions of polypharmacy available via Scopus and Pubmed databases. The Assessment of Multiple Systematic Reviews (AMSTAR) tool was used to appraise the methodological quality of the selected reviews. Available definitions and other characteristics were extracted; summarised in a table and analysed. Results: Six systematic reviews were identified. They were published between 2000 and 2018. Three focussed on definitions of polypharmacy in the elderly; two in the general population and one in children. The strategy adopted in reviews is more rigorous in the most recent ones. However, they remain, at best, partially exhaustive. The definitions found in the literature used two main approaches, either (i) quantitative, applying varying thresholds and types of polypharmacy based on the number of medications being taken by the patient (ii) qualitative, based on the clinical indications and effects of a given drug regimen, with a growing number of characteristics to describe polypharmacy. The term “inappropriate” is increasingly associated with polypharmacy especially in studies that aimed to use this definition to identify possible solutions for healthcare providers in the field related to aging. Conclusion: This review confirms a high variability and an evolution in the approaches defining “polypharmacy” in the absence of a consensus following standardized criteria. That makes it very difficult to estimate and measure the outcomes associated with this phenomenon.
- Subjects :
- Polypharmacy
education.field_of_study
Chemical Health and Safety
Actuarial science
business.industry
Population
Scopus
General Medicine
030204 cardiovascular system & hematology
3. Good health
03 medical and health sciences
0302 clinical medicine
Systematic review
Medicine
Pharmacology (medical)
030212 general & internal medicine
General Pharmacology, Toxicology and Pharmaceutics
Methodological quality
business
education
Safety Research
Healthcare providers
Drug regimen
Healthcare system
Subjects
Details
- ISSN :
- 1178203X
- Volume :
- 16
- Database :
- OpenAIRE
- Journal :
- Therapeutics and Clinical Risk Management
- Accession number :
- edsair.doi...........872e4d676d441f1a82c6ee09d151a231
- Full Text :
- https://doi.org/10.2147/tcrm.s214187